CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, today announced that data from the company’s Phase 2a clinical trial of ARC1779 will be presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco, Calif., December 6 to 9, 2008.
